Darrick Carter is the Vice President of Adjuvant Technology at IDRI. His work centers on new immunomodulatory agents and formulations, as well as the process development necessary to take vaccines and therapeutic candidates from the lab to the clinic.

Darrick is a biochemist/biophysicist with over 15 years of experience developing therapeutics and vaccines in the biotechnology industry. He has founded five companies, starting with a sole proprietorship biotech/internet startup, Proteinchemist.com, in 2001. Darrick previously worked at Corixa Corporation, where he led a new tuberculosis vaccine into human clinical trials and assisted as group leader for analytical biochemistry working on adjuvants and a commercial, radiolabeled mAb for non-Hodgkins lymphoma.

In 2004, he founded and served as CEO of PAI Life Sciences Inc., a bioinformatics company with proprietary drug discovery technologies using artificial neural nets. Darrick also served as Chief Scientific Officer at a specialty pharmaceutical company focused on drug and device combinations, is a founding member of a company focused on immunotherapy in oncology, and a founding member of a device company working on inflammatory disorders.